INFO & CONTACTS:  +39 02 2390 1

A phase II, open label, multicenter trial investigating Irinotecan plus cetuximab rechallenge compared with trifluridine/tipiracil plus bevacizumab as third line treatment in circulating tumor DNA molecularly selected metastatic colorectal cancer: the ROMANCE trial

Phase: Phase II clinical trials

Principal Investigator: Dott. Pietrantonio Filippo

Main Facility: Oncologia Medica Gastroenterologica

Drug: Irinotecan + cetuximab vs. trifluridina/tipiracil + bevacizumab

Pathologies: Intestinal cancer

ClinicalTrials.gov: Read the details about clinical trials

The ROMANCE trial is a phase II, prospective, randomised, multicentre study designed to evaluate two different treatment options for patients with metastatic colorectal cancer whose disease has progressed following standard therapies. The study compares re-exposure treatment with irinotecan plus cetuximab against the current standard of care, trifluridine/tipiracil plus bevacizumab, as third-line therapy. 

Patients enrolled in the study are selected based on specific molecular characteristics of their tumour, identified through analysis of circulating tumour DNA from a blood sample. In brief, patients who remain RAS/BRAF/EGFR/PIK3CA ex20/MAP2K1/MET WT and HER2-unamplified on baseline liquid biopsy using the FoundationOne CDx test will be randomly assigned in a 1:1 ratio to receive cetuximab, 500 mg/m², and intravenous irinotecan 180 mg/m², repeated every two weeks (Arm A) or trifluridine/tipiracil twice daily, 35 mg/m² on days 1–5 and 8–12 every 28 days plus bevacizumab 5 mg/kg on days 1 and 15 (Arm B). 

The primary aim of the study is to determine whether re-treatment with irinotecan and cetuximab results in a higher tumour response rate compared with the combination of trifluridine/tipiracil plus bevacizumab. Secondary objectives include the assessment of progression-free survival, overall survival, safety and quality of life. Patients will be randomly assigned to one of the two treatment groups and will receive treatment until disease progression, the occurrence of unacceptable side effects, or withdrawal of consent. Tumour response will be assessed using standard imaging techniques in accordance with RECIST criteria.

Last update: 16/07/2026

Subscribe to the newsletter

Sign up for our newsletter to stay informed about news, events, and updates from the Institute

Subscribe